Pomalidomide-PEG1-C2-COOH is primarily utilized in the development of targeted cancer therapies, particularly in the design of antibody-drug conjugates (ADCs). Its structure allows it to act as a linker, connecting cytotoxic agents to antibodies that specifically target cancer cells. This enables the precise delivery of therapeutic agents to tumor sites, minimizing damage to healthy tissues. The compound is also employed in research to enhance the solubility and stability of drugs, improving their pharmacokinetic properties. Additionally, it plays a role in the development of proteolysis-targeting chimeras (PROTACs), which are used to degrade disease-causing proteins selectively. Its applications extend to the study of immunomodulatory drugs, where it helps in understanding and optimizing drug delivery mechanisms for improved therapeutic outcomes.